Pacemaker Implantation Following Heart Transplantation – Incidence and Risk Factors. Single-Center Experience
Transplantation Proceedings · 2024
DOI: 10.1016/j.transproceed.2024.03.020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplantation Proceedings, 2024. Verfasst von Anna Boluk und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Heart Disease, Cardiothoracic Surgery Department, University Hospital, Wroclaw, Poland. Electronic address: anna.boluk@usk.wroc.pl. Hauptthemen laut MEDLINE: Heart Transplantation, Pacemaker, Artificial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Bradyarrhythmias, requiring pacemaker (PM) implantation, are common complications following orthotopic heart transplantation (HTx). Currently used heart transplantation methods are primarily the bicaval technique and the total heart transplantation technique. The aim of the study was to assess the incidence and risk factors, including donor parameters, of conduction disorders requiring pacing after HTx. METHODS: A population of 111 (52 ± 13 years, 91 (82%) men) heart recipients was divided into a group requiring PM implantation post-HTx and a group not requiring PM. We compared groups in terms of donor parameters, time of graft ischemia, transport and transplantation, and surgical techniques as the potential risk factors for significant bradyarrhythmias. RESULTS: Ten of 111 patients with HTx (9%) required PM implantation. The indication in 7 cases was sinus node dysfunction (SND), in 3 patients it was complete atrioventricular block (AV-block). In the PM group, the age of 48 ± 6 vs 40 ± 11 years (P = .0227) and the body mass index (BMI) 28 ± 3 vs 26 ± 4 kg/m2 (P = .0297) of the donor were significantly higher. There was no influence of organ transport time, ischemia time, and transplantation time. All patients requiring PM implantation were transplanted using the bicaval anastomosis: 10 (100%) vs 71 (70%) in the group not requiring PM (P = .044). CONCLUSIONS: The need for PM implantation post-HTx despite using new techniques is still common, especially in the group operated with the bicaval method. In addition, higher donor's age and BMI are risk factors of PM implantation, what is of importance as qualification criteria of donor hearts have been gradually extended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Institute of Heart Disease, Cardiothoracic Surgery Department, University Hospital, Wroclaw, Poland. Electronic address: anna.boluk@usk.wroc.pl.
- Institute of Heart Disease, Cardiothoracic Surgery Department, University Hospital, Wroclaw, Poland; Institute of Heart Disease, Wroclaw Medical University, Wroclaw, Poland.
- Institute of Heart Disease, Cardiothoracic Surgery Department, University Hospital, Wroclaw, Poland.
- Institute of Heart Disease, Wroclaw Medical University, Wroclaw, Poland; Institute of Heart Disease, Cardiology Department, University Hospital, Wroclaw, Poland.
Zitieren
APA
Boluk, A., Sokolski, M., Rakowski, M., Jura, M., Bochenek, M., Cielecka, M., Przybylski, R., & Zakliczyński, M. (2024). Pacemaker Implantation Following Heart Transplantation – Incidence and Risk Factors. Single-Center Experience. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2024.03.020
Vancouver
Boluk A, Sokolski M, Rakowski M, Jura M, Bochenek M, Cielecka M, et al. Pacemaker Implantation Following Heart Transplantation – Incidence and Risk Factors. Single-Center Experience. Transplantation Proceedings. 2024. doi:10.1016/j.transproceed.2024.03.020
BibTeX
@article{Boluk2024,
author = {Boluk, Anna and Sokolski, Mateusz and Rakowski, Mateusz and Jura, Maksym and Bochenek, Maciej and Cielecka, Magdalena and Przybylski, Roman and Zakliczyński, Michał},
title = {Pacemaker Implantation Following Heart Transplantation – Incidence and Risk Factors. Single-Center Experience},
journal = {Transplantation Proceedings},
year = {2024},
doi = {10.1016/j.transproceed.2024.03.020}
}
EUVIMED